AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM

Founding and Lead Sponsor in Collaboration with the   Vice Provost   of Advances in Learning at   Harvard University

The Amgen Foundation today announced an increased commitment to LabXchange, an online science education platform that provides users with access to high-quality science education resources at no cost. The Amgen Foundation is expanding its impact on science education with Harvard's Vice Provost of Advances in Learning by more than doubling their investment in LabXchange. As the founding and lead sponsor of LabXchange, the Amgen Foundation has committed $30 million to enhance science learning opportunities for students and educators worldwide in addition to the $13 million previously donated.

LabXchange was launched in January 2020 to help educators and students discover, engage with and share highly curated and personalized online lab experiments, interactive lessons and videos. With over 16,000 resources, these learning experiences complement in-person education to build science literacy and inspire the next generation of scientists.

"By overcoming barriers of cost and geographical location, LabXchange is helping to level the playing field, so learners of all ages everywhere have access to world-class science education," said Judy Brown , senior vice president of Corporate Affairs at Amgen and chairman for the Amgen Foundation.

"We believe that everyone needs science, and that science needs everyone. To date we've reached 20 million users in 230 countries and territories around the world," said Gaurav Vazirani , managing director at LabXchange. "To fully realize our vision, we aim to grow our global science classroom from 20 million people to 50 million by 2025."

The additional funding contribution will allow LabXchange to expand and deepen collaborations with STEM organizations worldwide, and pursue opportunities to serve more learners, particularly in communities that are underserved. Over the next three years, the investment will also allow LabXchange to:

  • Develop more data science, biotechnology and environmental content
  • Translate content into 30 languages
  • Launch a new teacher ambassador network
  • Increase content offerings that address racial inequity in healthcare, education and STEM
  • Expand content for middle schoolers

"COVID-19 has really pushed teachers to rethink their teaching strategies and a top priority for me was to make my classroom resources equitable for all students," said Uma Mahajan, a secondary educator in North Carolina . "LabXchange is a wonderful platform to simulate labs, access trusted resources and allow students to progress at their own pace."
For more information, please visit LabXchange.org .

About   LabXchange
LabXchange is an online science education platform that provides users with access to high-quality science education, personalized instruction, online lab experiences, and networking opportunities across the global scientific community at no cost. To learn more about this initiative, visit www.labxchange.org .

About the Amgen   Foundation
The Amgen Foundation is inspiring the next generation of scientists and future problem solvers – wherever they are. We are engaging students with diverse perspectives and backgrounds to harness the full potential of science to solve tomorrow's toughest challenges. Working in partnership with local and global partners, we are providing best-in-class science education at no cost to students. To date, the Foundation has donated over $375 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through its signature programs, including LabXchange, Amgen Scholars, and the Amgen Biotech Experience. For more information, visit www.AmgenFoundation.org and follow us on Twitter @AmgenFoundation .

About the Office of the Vice Provost for Advances in Learning, Harvard University  
Harvard's Office of the Vice Provost for Advances in Learning seeks to shape the future of education by discovering new ways to build the competence, curiosity, and confidence of learners on our campuses and around the world. We create engaging and scalable learning experiences, cultivate inspiring ideas, and connect a global community of learners while developing tools, technologies, platforms, and policies to reduce friction throughout the learning lifecycle.

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen Foundation.

CONTACT: Amgen, Thousand Oaks
Jessica Akopyan , 805-440-5721 (media)
Michael Strapazon , 805-313-5553 (media)
Annie Kasparian , 805-447-1060 (investors)

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-foundation-more-than-doubles-commitment-to-labxchange-free-virtual-science-education-platform-301570608.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

AMGN
The Conversation (0)
bctx stock

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.

Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independent Director for aTyr Pharmaceuticals (Nasdaq: LIFE), a biotechnology company developing novel therapeutics for respiratory diseases and multiple cancer indications.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Esperion Stock Increases After Investors Learn of Short FDA Approval Process

Esperion Therapeutics (NASDAQ:ESPR) shares increased by more than 10% after investors learned that the FDA will not require a long-term outcomes study prior to its potential approval of the company’s cholesterol-lowering drug.
According to Fierce Biotech:

Investors and analysts have been fretting over exactly what the FDA will do with ETC-1002, an LDL-lowering pill that is angling for a share of a blockbuster market many believe lies in wait for a new class of PCSK9 drugs. While the oral ETC-1002 may not be as effective as the PCSK9 drugs, including the newly-approved Praluent from Regeneron ($REGN) and Sanofi ($SNY) as well as a rival Amgen ($AMGN) drug, it also has a shot at grabbing a significant share of the market with a less expensive and more easily managed drug that could do everything many patients in this huge market require.
Overhanging all of these drugs has been a persistent fear that regulators would require a long-running cardiovascular outcomes trial to prove the therapy works as expected in improving patients’ health. But according to Esperion, the agency says it’s ready to give it a green light for a relatively narrow market–which still amounts to a patient pool of 9 million people–and then hold back on a broader approval until after the CVOT data comes in later.

Keep reading...Show less

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types

- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA IN SMALL CELL LUNG CANCER AT WCLC 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC

DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday Sept. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Appendix 4E and Preliminary Final Report - For the Year Ended 30 June 2024

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”) has released its Appendix 4E Preliminary Final Report.


Keep reading...Show less
Hydralyte

H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on the six-month period ended 30 June 2024 (the “half year” or “H1 FY2024”) and the Company’s Appendix 4D.

Keep reading...Show less

Latest Press Releases

Related News

×